China
Africa
Explore chapters and articles related to this topic
Innovations and Future Prospects of Dermal Delivery Systems
Published in Tapash K. Ghosh, Dermal Drug Delivery, 2020
Rashmi Upasani, Anushree Herwadkar, Neha Singh, Ajay K. Banga
In order to improve the performance and patient compliance of the solid transdermal (patch) dosage form, several new technologies have been investigated in recent years. Aveva DDS novel Crystal Reservoir Technology has been able to provide controlled, sustained release of drugs having a consistent supply of drug in each patch. This technology is based on the concept of oversaturation of the adhesive polymer in the patch with the drug resulting in partial drug crystallization. The patch thus contains dissolved drug molecules as well as drug crystals in the adhesive layer. As drug delivery progresses, the drug crystals would re-dissolve to maintain saturation conditions in the patch ensuring consistent and maximum thermodynamic activity for percutaneous drug permeation. This technology could thus translate into production of aesthetic – smaller and thinner patches improving patient compliance (Hadgraft et al. 2006). An additional advantage of the Crystal Reservoir Technology includes the ability to attain various patterns of drug release. Sustained drug release can be obtained due to the presence of excess drug in the adhesive polymer. Nitto Denko has incorporated this technology into different types of release systems. Isosorbide dinitrate, an anti-anginal agent, has been formulated using this transdermal system by Nitto Denko which allows increased patient compliance, and the use of Lipo-gel adhesive reduces skin irritation. Similarly burst release (rapid release of drug on the surface of skin) and chrono-controlled release (release based on state of disease and need of the patient) have been achieved using the Crystal Reservoir Technology. Lidocaine and tulobuterol transdermal systems, developed by Nitto Denko, are burst and chrono-controlled release respectively as these release patterns help in exercising a better control over delivery of these local anesthetic agents meant to alleviate pain in patients (Pecha et al. 2000).
Chest tightness is relieved with the use of asthma drugs except bronchodilators
Published in Journal of Asthma, 2019
Hirokazu Taniguchi, Yuko Nakanishi, Takeshi Tsuda, Yasuaki Masaki, Hideaki Furuse, Kensuke Suzuki, Shin Ishizawa, Atsushi Muto, Mami Shimizu, Tomomi Ichikawa, Hideki Miyazawa
CTRB was diagnosed by noting an improvement in chest tightness after inhalation of a short-acting ß2-agonist (SABA, 0.03 mg procaterol hydrochloride) or administration of a long-acting ß2-agonist (2 mg/day tulobuterol patch).